Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (NASDAQ: FLGT) regularly issues news and updates that reflect its dual focus on laboratory services and oncology therapeutic development. Company press releases cover topics such as quarterly and annual financial results, clinical trial progress for its cancer drug candidates, regulatory milestones for its genomic testing platforms, and strategic transactions in the laboratory and pathology space. Because Fulgent describes itself as a technology-based company with ambitions in precision medicine, its news flow often highlights both operational performance and advances in its technology and therapeutic pipelines.
Investors following FLGT news can expect detailed earnings releases that discuss revenue, core revenue, GAAP and non-GAAP results, gross margins, and adjusted EBITDA, along with commentary from management on business trends in the laboratory services and therapeutic development segments. The company also announces the timing of upcoming earnings calls and investor conference presentations through news releases, providing context for when management will discuss the business with the investment community.
Beyond financial reporting, Fulgent’s news includes updates on its oncology programs, such as preliminary clinical data from trials of FID-007 in recurrent or metastatic head and neck squamous cell carcinoma. The company also reports on regulatory achievements, including CE certification in the European Union for its FulgentExome and Fulgent Pipeline Manager (PLM) germline next-generation sequencing system. In addition, Fulgent uses press releases to announce strategic moves in laboratory and pathology services, such as its agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx.
This FLGT news page aggregates these types of announcements so readers can review financial disclosures, clinical development updates, technology milestones, and transaction-related news in one place. For those tracking Fulgent’s progress toward its stated goal of becoming a fully integrated precision medicine company, the news feed provides an ongoing view of how the company reports its operational and strategic developments.
Fulgent Genetics (NASDAQ: FLGT) completed the acquisition of Bako Diagnostics and StrataDx on March 17, 2026. The company acquired certain assets of Bako and purchased StrataDx for a combined cash purchase price of approximately $56.9 million, subject to post-closing adjustments.
The acquisitions add a premier pathology laboratory and a premier dermatopathology laboratory to Fulgent's laboratory services businesses. Financial and legal advisors to both sides were disclosed.
Fulgent Genetics (NASDAQ: FLGT) reported Q4 2025 revenue of $83.3M (+9% YoY) and FY 2025 revenue of $322.7M (+14% YoY). GAAP loss for FY was $60.5M (loss of $1.97/share); non-GAAP income was $13.2M ($0.42/share). Cash and equivalents totaled $705.5M excluding an expected ~$106.3M tax refund. Management flagged a large customer moving volume in-house and provided 2026 guidance: revenue ~$350M, non-GAAP loss ~$(1.45) per share, and pro forma cash ~$685M, assuming a ~$56M acquisition spend for Bako and Strata Dx.
Fulgent Genetics (NASDAQ: FLGT) will release fourth quarter and full year 2025 financial results before the market opens on Friday, February 27, 2026.
Management will host a conference call the same day at 8:30 AM ET (5:30 AM PT) with a live audio webcast and an audio replay available on the company Investor Relations website.
Fulgent Genetics (NASDAQ: FLGT) agreed to acquire selected assets of Bako Diagnostics and to acquire StrataDx for a combined purchase price of approximately $55.5 million, payable from cash on hand. The deals are expected to close in the first half of 2026, subject to customary closing conditions including regulatory approvals.
The acquisitions add anatomic and dermatopathology services, proprietary PCR tests, CLIA/CAP/NY-certified labs in Georgia and Massachusetts, and a national salesforce that will nearly double Fulgent’s pathology sales team, while enabling further use of Fulgent’s Eziopath image management and AI tools.
Fulgent Genetics (NASDAQ: FLGT) said members of management will present at two investor conferences in November and December 2025. Presentations are scheduled for the UBS Global Healthcare Conference on Monday, November 10, 2025 at 5:00 PM ET and the Piper Sandler 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 11:00 AM ET.
Live webcasts and replays will be available on the company's Investor Relations website at ir.fulgentgenetics.com, with replays posted about one hour after each event ends.
Fulgent (NASDAQ: FLGT) reported Q3 2025 revenue of $84.1M, up 17% year-over-year, GAAP loss of $6.6M (−$0.21/share) and Non-GAAP income of $4.5M ($0.14/share). Adjusted EBITDA was $0.7M. The company raised full-year 2025 revenue guidance to $325.0M, updated GAAP EPS guidance to a loss of approximately ($1.70) and Non-GAAP income guidance to $0.30 per share. Cash and investments totaled $787.7M at quarter end, with an expected year-end cash position of about $800.0M assuming receipt of roughly $106M in tax refunds.
Company highlighted therapeutic progress on FID-007 and FID-022 and will hold an investor call today.
Fulgent Genetics (NASDAQ: FLGT) reported preliminary phase 2 data (cutoff Sept 25, 2025) for FID-007 plus cetuximab in ≤2nd-line recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Key datapoints: 39 patients randomized, 36 dosed; 35 evaluable for efficacy. Objective response rates (ORR) were 44% at 75 mg/m2, 59% at 125 mg/m2, and 51% overall. Median progression-free survival (PFS) was 9.2 months (75 mg/m2), 7.8 months (125 mg/m2) and 7.8 months overall, versus a historical PFS of 2.3 months. Safety: 6% treatment-related serious adverse event rate; selected grade ≥3 treatment-related events included lymphocyte count decreased 19% and neutrophil count decreased 17%. An optimal dose will be selected after data maturation.
Fulgent Genetics (NASDAQ: FLGT) will release its third quarter 2025 financial results before the market opens on Friday, November 7, 2025. Management will host a conference call the same day at 8:30 AM ET (5:30 AM PT) to discuss results and answer investor questions.
The call is accessible via a live audio webcast on the company Investor Relations site at http://ir.fulgentgenetics.com, and an audio replay will be available at the same location.
Fulgent Genetics (NASDAQ: FLGT) reported its Q2 2025 financial results, with core revenue growing 16% year-over-year to $81.7 million. The company posted a GAAP loss of $19.0 million (($0.62) per share) but achieved non-GAAP income of $2.1 million ($0.07 per share).
Key highlights include a strong cash position of $777.5 million in cash and investments, continued share repurchases of approximately 130,000 shares at $2.2 million, and raised full-year 2025 guidance to $320 million in core revenue. The company maintained solid gross margins with GAAP gross margin of 42.1% and non-GAAP gross margin of 44.2%.
Management expressed confidence in the company's growth trajectory, citing progress in both Laboratory Services and Therapeutic Development businesses.
Fulgent Genetics (NASDAQ: FLGT) has achieved CE certification under the EU's In Vitro Diagnostic Regulation for its germline next-generation sequencing system, including FulgentExome and Fulgent Pipeline Manager (PLM). The company may be the first laboratory to receive CE mark for such a comprehensive end-to-end germline testing offering, validating over 4,600 genes for diagnostic use.
FulgentExome is designed to examine coding regions and splice junctions, focusing on clinically relevant variants to aid in diagnosing suspected genetic conditions. The Fulgent PLM software works within the FulgentExome system to analyze genetic sequencing data. This certification enables Fulgent to expand its services throughout Europe and potentially support clinical trials and reimbursement pathways under IVDR.